Datapoint: FDA Approves Merck’s Tepmetko for NSCLC Mutation

The FDA last week approved Merck KGaA’s Tepmetko for the treatment of non-small cell lung cancer with MET exon 14 skipping mutations, an aggressive form of the disease which affects between 3% and 4% of NSCLC patients, according to a press release from the drugmaker. The drug will have to face off against Novartis’s Tabrecta, which scored the first-in-class nod in May 2020. Under the pharmacy benefit, Tabrecta currently holds preferred formulary placement for 4% of covered lives, growing to 14% with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 2/8/21

0

0

0 Comments

0

0

• Datapoint